Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
61
resultados
Última actualización
21/11/2024 [07:49:00]
Resumen de: EP4465045A2
The present invention provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating dieseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
Resumen de: EP4465050A2
The invention provides anti-Tau antibodies and methods of using the same.
Resumen de: MX2024008594A
The present disclosure provides methods of treating subjects having Alzheimer's Disease, and methods of identifying subjects having an increased risk of developing Alzheimer's Disease.
Resumen de: AU2023207441A1
The invention relates to an
Resumen de: AU2023308198A1
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: WO2024231628A1
The invention relates to a method for the early in vitro diagnosis of a neurodegenerative disease in a human or an animal subject, the method comprising the step of detecting the presence of at least one marker chosen from among forms derived from amyloid beta peptides (Aβ) chosen from among the oligomers of these peptides and the prefibrillar and fibrillar aggregate forms of these peptides, and forms derived from phosphorylated tau proteins chosen from among the hyperphosphorylated forms of these proteins, the aggregate forms of these proteins and the modified phosphorylated tau proteins resulting from one or more post-translational modifications, the presence of the one or more markers being detected in a stool sample from this subject.
Resumen de: US2024376530A1
The present disclosure provides methods and systems for mapping gene and protein expression in a cell (i.e., mapping gene and protein expression within the same cell simultaneously). The present disclosure also provides methods for diagnosing a disease or disorder (e.g., a neurological disorder such as Alzheimer's disease) in a subject. Methods of screening for a candidate agent capable of modulating gene and/or protein expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder, such as Alzheimer's disease, in a subject in need thereof. A plurality of oligonucleotide probes, which may be useful for performing the methods described herein, are also described by the present disclosure, as well as kits comprising any of the oligonucleotide probes described herein. Additionally, the present disclosure provides methods, apparatuses, and non-transitory computer-readable storage media for identifying spatial variations of cell types in at least one image.
Resumen de: US2024376188A1
The invention relates to monoclonal antibodies or an antigen binding fragment thereof targeting acetylation sites within the human Tau protein. K280 and K311, which can be indicative of a disease state and, as such, represent diagnostic and/or therapeutic targets. Accordingly, one aspect of the invention relates to a monoclonal antibody or an antigen binding fragment thereof that specifically binds acetylated lysine 280 or acetylated lysine 311 in human tau protein. The monoclonal antibody or an antigen binding fragment thereof can be part of a pharmaceutical composition and provided to a subject to diagnose and/or treat a tauopathy.
Resumen de: EP4462124A2
Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.
Resumen de: FR3148478A1
L’invention concerne un procédé pour le diagnostic in vitro d’une maladie neurodégénérative, chez un individu humain ou animal, et un procédé de criblage d’un médicament pour traiter une maladie neurodégénérative, lesdits procédés comprenant l’étape qui consiste à détecter la présence d’au moins un marqueur choisi parmi les peptides béta-amyloïdes (Aβ), les formes dérivées desdits peptides, les protéines tau phosphorylées et les formes dérivées desdites protéines, dans un échantillon de selles dudit individu.
Resumen de: US2024369580A1
The present invention generally relates to method for evaluating and improving cognitive function in a subject. In particular, the invention generally relates to methods for evaluating cognitive function in a subject by determining the level of cholesteryl esters in a subject, and to improving cognitive function in a subject comprising the administration of cholesteryl oleate, or analogues thereof.
Resumen de: US2024369577A1
The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).
Resumen de: US2024369578A1
The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.
Resumen de: US2024369583A1
An Alzheimer's disease biomarker, and a screening method therefor and use thereof. The Alzheimer's disease biomarker is 11(Z), 14(Z)-eicosadienoic acid. The screening method for the Alzheimer's disease biomarker comprises: acquiring samples, testing the samples, and performing structural identification and data analysis on metabolites in the samples, wherein specifically, metabolites in faeces samples can be tested by liquid chromatography-mass spectrometry, to carry out structural identification on the metabolites; and selecting a metabolite showing a difference from the metabolite level of a control group as the Alzheimer's disease biomarker. Using 11(Z), 14(Z)-eicosadienoic acid as an Alzheimer's disease biomarker is of great significance to clinical early diagnosis of Alzheimer's disease; the present invention can be used for preparing a diagnostic tool for Alzheimer's disease, predicting the individual treatment effects of patients with Alzheimer's disease, and preparing drugs for treating Alzheimer's disease.
Resumen de: US2024369546A1
The present application relates to a erythrocyte-derived magnetic immune particle and uses thereof, according to an aspect, the erythrocyte-derived magnetic immune particle include an erythrocyte-derived cell membrane, which may minimize in vivo side effect, and may be used to detect and remove various type of substances (for example, a pathogenic substance, an inflammatory cytokine, blood glucose, a cancer-related substance, and a brain disease-related substance, etc.) from a sample with excellent efficiency, which may be useful for diagnosing, preventing, or treating various type of diseases, including an infectious disease, an inflammatory disease, diabetes, cancer, and brain disease.
Resumen de: AU2022429793A1
Provided are methods for diagnosing and/or treating Alzheimer's disease. Also provided are biomarkers, and combinations of biomarkers, that are diagnostic for the presence and progression of Alzheimer's disease, and treatment thereof.
Resumen de: US2024361307A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: US2024360318A1
Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, and analysis of molecular chaperone activity.
Resumen de: US2024361340A1
The present invention relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay according to the present invention that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the biomarker in the sample. The present invention also relates to methods of determining the state of a subject's neural injury. The present invention also relates to systems and devices useful in carrying out the methods of the present invention.
Resumen de: US2024360206A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2024358805A1
Described herein are methods for making and using antibodies that bind specifically to soluble oligomers of amyloid beta protein (oAβ), and methods of use thereof in diagnosis and treatment of diseases related to formation of pathogenic oligomers of oAβ. Also provided are T helper cell (Th) carrier peptides that can be conjugated to peptide immunogens to stimulate targeted humoral immune responses to the desired antigen.
Resumen de: WO2024224066A1
The invention relates to a peptide derivative of Formula (I). The peptide derivative may be used in treating, ameliorating or preventing a neurodegenerative disorder, such as Alzheimer's disease; Parkinson's disease; Huntington's disease; motor neurone disease; Spinocerebellar ataxia (SCA) type 1, type 2, and type 3; Amyotrophic Lateral Sclerosis (ALS); schizophrenia; Lewy-body dementia; and Frontotemporal Dementia.
Resumen de: AU2022408967A1
Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAXTM effectively improved the sensory function in patients with diabetic neuropathy.
Resumen de: CA3242558A1
Aspects of the application relate to methods and systems for obtaining information regarding multiple amino acids in a polypeptide based on binding interactions between the polypeptide and one or more amino acid recognizers. Kinetic signature information may be obtained from a series of signal pulses indicative of a series of binding events between one or more amino acid recognizers and an amino acid of a polypeptide (e.g., a terminal amino acid, an internal amino acid). The kinetic signature information (e.g., pulse duration, interpulse duration, recognition segment (RS) duration, intersegment duration) may be used to determine one or more chemical characteristics (e.g., identity, modification) of multiple amino acids of the polypeptide.
Nº publicación: US2024352414A1 24/10/2024
Solicitante:
WASHINGTON UNIV [US]
Washington University
Resumen de: US2024352414A1
Provided herein are methods of making and using reprogrammed neuronal cells and neuronal spheroids from patient-derived somatic cells in 3D-cultures, by expressing at least one neurogenic miRNA and optionally at least one neurogenic transcription factor.
BOPI
Sede Electrónica
